Head and Neck Cancer (HNC) Pharynx

$ 8.690,00

Head and Neck Cancer (HNC) Pharynx

The Head and Neck Cancer (HNC) Pharynx represents multiple anatomical sites in the head and neck region, includes only Pharynx. In the G7 mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK), Hoffmann-Krueger epidemiologists expect the incident cases of HNC (Pharynx) cancer to increase from 101 128 cases in 2012 to 101 927 cases in 2022.

  • Countries concerned :

Add to my wishlist

Scope: G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)

10-year patient population forecast + 5 years of historical data

 

Key Users:  Oncology Market Research - New Product Planning - Business Development & Licensing

Oncology Market Access – Oncology Marketing leaders

 

Insight: Insight into the Head and Neck (Pharynx) cancer strategy and business development activities

Transparent forecasts methodology and assumptions

Concise and comparable analysis

 

Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.

 

The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.

 

Reasons To Buy

 Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

 

  • Country : Germany | United States | Spain | Italy | France | United Kingdom | Japan
  • Cancer Type : HNC OC Pharyn
  • File : xls